Vinding T, Nielsen N V
Acta Ophthalmol (Copenh). 1983 Feb;61(1):45-50. doi: 10.1111/j.1755-3768.1983.tb01393.x.
In 17 patients treated with tamoxifen in a low dosage (30 mg daily) ophthalmological examination was performed. This revealed 2 cases with possible retinotoxic effect. A 64 year-old woman treated with tamoxifen for 9 months for metastatic breast cancer developed retinopathy with transitory visual impairment. The retinopathy was morphological characterised by multiple yellowish-white dots in the posterior pole, a parafoveal haemorrhage and accumulation of reticular pigment changes in the periphery of the retina. By retinal fluorescein angiography multiple non-fluorescent dots and hyperfluorescent areas were seen in the posterior pole. The retinal lesions remained unchanged except for the haemorrhage after discontinuation of the tamoxifen treatment. In another patient some of these changes were also found. The retinotoxic effect of tamoxifen has been reported previously with tamoxifen in high dosage (greater than or equal to 180 mg daily, minimal total dosage of 90 g) used for long periods, but never from this drug in low dosage (30 mg daily, minimal total dose 8.1 g-12.0 g).
对17例接受低剂量(每日30毫克)他莫昔芬治疗的患者进行了眼科检查。结果发现2例可能存在视网膜毒性作用。一名64岁女性因转移性乳腺癌接受他莫昔芬治疗9个月,出现视网膜病变并伴有短暂视力损害。该视网膜病变的形态学特征为后极部有多个黄白色小点、黄斑旁出血以及视网膜周边部网状色素改变积聚。通过视网膜荧光血管造影,在后极部可见多个无荧光小点和高荧光区。停用他莫昔芬治疗后,除出血外,视网膜病变保持不变。在另一名患者中也发现了其中一些变化。他莫昔芬的视网膜毒性作用此前曾在长期使用高剂量(每日大于或等于180毫克,最小总剂量90克)他莫昔芬的情况下被报道,但从未在低剂量(每日30毫克,最小总剂量8.1克 - 12.0克)使用该药物时出现过。